Use of H19 regulatory sequences for targeted gene therapy in cancer

Area of Science:

• Oncology
• Gene Therapy
• Molecular Biology

Background:

• The H19 gene exhibits differential expression between normal and cancerous cells, making its regulatory sequences potential targets for cancer gene therapy.
• Developing targeted gene therapies requires precise control over therapeutic gene expression within tumor cells.

Purpose of the Study:

• To develop and evaluate a tumor gene therapy strategy utilizing the H19 gene's regulatory sequences.
• To assess the therapeutic efficacy and toxicity of expression vectors containing diphtheria toxin A (DT-A) or herpes simplex virus thymidine kinase (HSV-tk) genes under H19 control.

Main Methods:

• Constructed expression vectors with DT-A or HSV-tk genes driven by an 814 bp 5'-flanking region of the H19 gene.
• Evaluated the cell-killing activity of these constructs in vitro, correlating it with H19 regulatory sequence activity.
• Assessed therapeutic potential in a syngeneic animal model of bladder cancer via intratumoral injection of the constructs.

Main Results:

• The cell-killing efficacy of the constructs aligned with the activity of the H19 regulatory sequences in transfected cells.
• Intratumoral administration of H19-driven gene expression constructs significantly suppressed subcutaneous tumor growth in the bladder cancer model.
• No significant toxicity was observed in the host animals, indicating a favorable safety profile.

Conclusions:

• The H19 gene's regulatory sequences can effectively drive therapeutic gene expression for targeted cancer therapy.
• This H19-based gene therapy approach demonstrates significant potential for treating bladder cancer with minimal host toxicity.